Cavernous sinus thrombosis is a rare, life-threatening thrombophlebitic disease with an incidence of 0.2–1.6 per 100,000 and contemporary mortality of approximately 11%, with morbidity (persistent neurological deficits) in ~15–30% of survivors. [1-3] The most common etiology is septic CST arising from paranasal sinusitis or facial infections, though aseptic causes (thrombophilia, malignancy, dehydration) also occur. [1][4-5] A high index of clinical suspicion remains the cornerstone of timely diagnosis. [6]
The following table summarizes the frequency of clinical findings in septic CST:
1. History
- Key HPI questions: Ask about recent sinusitis, dental infection, facial abscess, boil/furuncle on the face (especially in the "danger triangle"), ear infection, or recent facial/sinus surgery [1][4]
- Symptom characterization: Headache (present in >90%), typically progressive over days; periorbital/forehead pain; eye swelling; double vision; vision loss [1][7]
- Timing: Symptoms of the primary infection typically precede CST by 5–10 days; mean time from presentation to diagnosis is ~2.8 days, and >64% of cases are diagnosed >7 days after symptom onset [8-9]
- Progression: Unilateral ocular symptoms that progress to bilateral involvement are highly characteristic — thrombosis spreads via the intercavernous sinuses to the contralateral side [6]
- Associated symptoms: Fever, nausea/vomiting, altered mental status, seizures [1][5]
- Important negatives: Absence of trauma, no history of recent travel/immobilization, no oral contraceptive use (helps distinguish septic from aseptic causes)
2. Alarm Features
- Bilateral eye involvement — near-pathognomonic for CST when combined with fever and recent facial/sinus infection [6]
- Rapidly progressive proptosis, chemosis, and ophthalmoplegia [1][7]
- Altered mental status or declining GCS — suggests intracranial extension (meningitis, cerebral abscess, extension to petrosal sinuses with brainstem signs) [7][10]
- New relative afferent pupillary defect (RAPD) — associated with significantly worse visual outcomes and higher mortality (37.5% vs 0%) [3]
- Vision loss — suggests optic nerve compromise from elevated intraorbital pressure
- Signs of sepsis (hemodynamic instability, high fever, rigors)
- Seizures or focal neurological deficits beyond cranial nerves III–VI [5][7]
3. Medications
- Relevant contributors: Oral contraceptives/estrogen-containing hormonal therapy (8-fold increased CVT risk), corticosteroids, L-asparaginase [5]
- Core treatments:
- IV antibiotics — broad-spectrum empiric coverage targeting Staphylococcus aureus (including MRSA), streptococci, anaerobes, and gram-negatives. Vancomycin is the most commonly used agent; typically combined with a third-generation cephalosporin and metronidazole [1][3][8]
- Anticoagulation — heparin (UFH or LMWH) in the acute phase; adjusted OR for mortality with anticoagulation is 0.067 (95% CI 0.009–0.475) [5][11]
- Corticosteroids — role remains controversial; not routinely recommended by AHA guidelines but sometimes used for severe orbital inflammation [2][7]
- Contraindicated: Avoid non-heparin anticoagulants if HIT/VITT is suspected — use alternative agents and test for anti-PF4 antibodies [7]
4. Diet
- Hydration is critical — dehydration is a recognized risk factor for CVT and should be aggressively corrected with IV fluids [1][5]
- No specific dietary triggers or restrictions apply to CST itself
- Long-term: if on warfarin for anticoagulation, counsel on consistent vitamin K intake
5. Review of Systems
- HEENT: Nasal congestion/discharge, facial pain/pressure, dental pain, ear pain/drainage, sore throat (source of infection) [1][4]
- Ophthalmologic: Diplopia, blurred vision, vision loss, eye pain, periorbital swelling [1][7]
- Neurologic: Headache character/progression, confusion, seizures, focal weakness, numbness (V1/V2 distribution) [5][7]
- Constitutional: Fever, chills, rigors, malaise, weight loss
- Pulmonary: Cough, dyspnea, pleuritic chest pain (septic pulmonary emboli can occur) [1]
- Hematologic: Easy bruising, prior DVT/PE (thrombophilia screening)
6. Collateral History and Family History
- Confirm timeline of preceding infection and any prior antibiotic use
- History of immunocompromise (diabetes mellitus present in ~70% of cases in some series, HIV, malignancy) [9]
- Family history of thrombophilia — factor V Leiden, prothrombin G20210A, protein C/S deficiency [5]
- Social history: IV drug use, recent dental procedures, facial manipulation (e.g., popping facial lesions in the "danger triangle")
7. Risk Factors
- Sinusitis (especially sphenoid and ethmoid) — most common precipitant [1][4][12]
- Facial infections: Furuncles, dental abscess, orbital/periorbital cellulitis, otitis media, mastoiditis [1][6]
- Diabetes mellitus — present in up to 70% of septic CST cases [9]
- Immunosuppression (chemotherapy, HIV, chronic steroid use)
- Thrombophilia — inherited (factor V Leiden, protein C/S deficiency) or acquired (antiphospholipid syndrome, malignancy, OCP use) [5]
- Maxillofacial trauma or surgery [1]
- Dehydration [1][5]
- COVID-19 infection and VITT (vaccine-induced thrombotic thrombocytopenia) [5]
8. Differential Diagnosis
- Orbital cellulitis — most important mimic; CST should be suspected when orbital cellulitis is bilateral, rapidly progressive, or unresponsive to antibiotics [8]
- Orbital apex syndrome — similar cranial nerve involvement but typically without fever or systemic toxicity
- Mucormycosis (rhinocerebral) — especially in diabetic or immunocompromised patients; black eschar on palate/turbinates is a distinguishing feature
- Tolosa-Hunt syndrome — painful ophthalmoplegia from granulomatous inflammation of the cavernous sinus; diagnosis of exclusion, steroid-responsive
- Carotid-cavernous fistula — pulsatile proptosis, orbital bruit, arterialized conjunctival vessels
- Pituitary apoplexy — sudden headache, ophthalmoplegia, visual field deficits
- Meningitis — may coexist with CST; isolated meningitis lacks the orbital findings [10]
- Periorbital/preseptal cellulitis — lacks proptosis, ophthalmoplegia, and systemic toxicity
9. Past Medical History
- Prior episodes of sinusitis, orbital cellulitis, or facial infections
- History of DVT/PE or recurrent thrombosis
- Known thrombophilia or hypercoagulable state
- Diabetes mellitus — strongly associated [9]
- Autoimmune disease (Behçet, IBD, antiphospholipid syndrome) [5]
- Malignancy, especially myeloproliferative disorders
- Recent surgery (especially head/neck/sinus)
- Pregnancy or postpartum state
10. Physical Exam
- Vitals: Fever (present in majority), tachycardia; hypotension suggests sepsis
- Eyes:
- Proptosis — often unilateral initially, progressing to bilateral [7-8]
- Chemosis (conjunctival edema/injection) [1][7]
- Periorbital edema [1]
- Ptosis [1][13]
- Ophthalmoplegia — CN VI (lateral rectus) palsy is most common; CN III and IV also affected [1][7]
- Elevated intraocular pressure (>21 mmHg in ~54%) [3]
- RAPD — check carefully; prognostic significance [3]
- Fundoscopy: papilledema, dilated retinal veins, disc edema
- Face: Examine for source — nasal discharge, facial tenderness over sinuses, dental caries/abscess, skin lesions in the "danger triangle"
- Neurologic: Assess V1/V2 sensation (ophthalmic and maxillary divisions of CN V), mental status, signs of meningismus [7]
- Contralateral eye involvement is a critical finding that strongly suggests CST [6]
11. Lab Studies
- Blood cultures — positive in up to 70% of septic CST cases; obtain before antibiotics [1]
- CBC with differential — leukocytosis expected
- CRP and ESR — elevated inflammatory markers [1]
- Procalcitonin — may help distinguish septic from aseptic etiology
- BMP — assess renal function (contrast imaging, anticoagulation dosing)
- Coagulation studies — PT/INR, aPTT (baseline before anticoagulation)
- D-dimer — elevated in CVT; a normal D-dimer has limited negative predictive value in high clinical suspicion [5]
- Thrombophilia workup (if aseptic or no clear infectious source): antiphospholipid antibodies, factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin III, JAK2 mutation [5]
- Lumbar puncture — if meningitis is suspected; CSF may show pleocytosis and elevated protein [10]
- Anti-PF4 antibodies — if HIT or VITT is suspected [7]
12. Imaging
- First-line (ED setting): CT head and orbits with IV contrast (delayed-phase imaging) — look for filling defects in the cavernous sinus, expansion of the cavernous sinus, convexity of the lateral wall, and the "empty delta sign" [1][5][9]
- Also evaluate for sinusitis, orbital abscess, or other source of infection
- Non-contrast CT alone has limited sensitivity (~60–80%) [14]
- Gold standard: MRI brain with MR venography (contrast-enhanced preferred) — highest sensitivity for CST and better characterization of parenchymal complications (venous infarction, hemorrhage) [1][5][15]
- Key imaging findings:
- Filling defect within the cavernous sinus
- Expansion/asymmetry of the cavernous sinus
- Convexity of the lateral wall [9]
- Associated sinusitis, orbital inflammation
- Venous infarction or hemorrhage if thrombosis extends
- When imaging is unnecessary: Imaging should never be deferred when CST is clinically suspected — this is a do-not-miss diagnosis
The following figure from the NEJM illustrates key imaging findings in cerebral venous sinus thrombosis, including the "empty delta sign":
13. Special Tests
- Point-of-care ultrasound (POCUS): Ocular ultrasound may demonstrate proptosis, dilated optic nerve sheath (elevated ICP), and retrobulbar abnormalities
- Digital subtraction angiography (DSA): Reserved for cases where non-invasive imaging is equivocal or endovascular intervention is planned [5]
- Thrombophilia panel: As above, particularly in aseptic cases or recurrent thrombosis [5]
- Sinus/wound cultures: If surgical drainage is performed
14. ECG
- ECG is not a primary diagnostic tool for CST
- Obtain ECG as part of sepsis workup to evaluate for tachycardia, arrhythmias, or signs of right heart strain (if septic pulmonary emboli are suspected)
- No specific ECG pattern is associated with CST
15. Assessment
- CST is a clinical diagnosis confirmed by imaging — maintain a high index of suspicion in any patient with headache, fever, and ocular findings in the setting of recent facial/sinus infection [1][6]
- Severity stratification:
- Mild: unilateral orbital signs, preserved vision, stable mental status
- Severe: bilateral involvement, vision loss, RAPD, altered mental status, sepsis, intracranial complications (meningitis, abscess, venous infarction) [3]
- Typical presentation: Subacute onset of unilateral periorbital pain/swelling → progressive ophthalmoplegia → contralateral spread over days [6]
- Atypical presentations: Isolated headache, indolent course (especially in aseptic CST or fungal etiologies like Aspergillus in immunocompromised patients) [9]
- Complications: Meningitis, brain abscess, carotid artery narrowing/stroke, pituitary insufficiency, septic pulmonary emboli, permanent vision loss, persistent cranial nerve palsies, death [1][3][10]
16. Treatment Plan
Initial stabilization
- ABCs, IV access, fluid resuscitation
- Continuous monitoring if hemodynamically unstable or altered mental status
Antibiotics (start empirically immediately)
- Vancomycin (MRSA coverage) + third-generation cephalosporin (e.g., ceftriaxone) + metronidazole (anaerobic coverage) [1][8][12]
- Adjust based on culture results; typical IV antibiotic course is 3–4 weeks minimum, often 6 weeks [3][8]
- Add antifungal coverage (amphotericin B) if mucormycosis or Aspergillus is suspected [9]
Anticoagulation
- Heparin (UFH or LMWH) — initiate as soon as CST is confirmed; strong evidence supports reduced mortality (adjusted OR 0.067) [5][11][16]
- LMWH is generally preferred over UFH (more predictable effect, lower HIT risk) [5]
- Transition to oral anticoagulation (warfarin, target INR 2.0–3.0) for 3–6 months for transient risk factors; longer if chronic thrombophilia [5][16]
- Anticoagulation is recommended even in the presence of hemorrhagic venous infarction [16]
Surgical intervention
- Endoscopic sinus surgery or surgical drainage of the infectious source when applicable (sinusitis, abscess) [8][10][12]
- Performed in up to ~80% of cases in some series [3]
Adjunctive
- Corticosteroids — not routinely recommended; may be considered for severe orbital inflammation on a case-by-case basis [2][7]
- Anticonvulsants if seizures occur [7]
17. Disposition
- All patients with confirmed or suspected CST require ICU-level admission [1][6]
- Average length of hospitalization is approximately 21 days [8]
- Specialist consultation triggers:
- Neurosurgery — for intracranial complications, consideration of endovascular intervention
- ENT/Otolaryngology — for surgical drainage of sinusitis or other source
- Ophthalmology — for vision assessment, IOP management
- Infectious disease — for antibiotic optimization
- Hematology — if thrombophilia workup is needed or anticoagulation management is complex
- Observation is not appropriate — this is a high-acuity condition requiring aggressive inpatient management
18. Follow Up / Return Precautions
- Follow-up timing: Ophthalmology and neurology follow-up within 1–2 weeks of discharge; repeat imaging (MRV) at 3–6 months to assess for recanalization [5]
- Anticoagulation monitoring: INR checks if on warfarin; reassess duration at 3–6 months based on recanalization and risk factor status [5][16]
- Symptoms requiring immediate reassessment:
- New or worsening headache, vision changes, or diplopia
- Fever recurrence
- Altered mental status or seizures
- Signs of bleeding (on anticoagulation)
- Patient counseling:
- Majority of patients experience some degree of neurological sequelae (~30% persistent EOM limitation, ~17% persistent vision loss) [3]
- Full recovery is possible with early treatment, but prolonged rehabilitation may be needed
- Avoid OCP/estrogen-containing therapies if thrombophilia is identified [5]
- Expected recovery: Clinical improvement typically begins within days of appropriate therapy, but complete resolution of cranial nerve deficits may take weeks to months [8]
References
1. High Risk and Low Prevalence Diseases: Cavernous Sinus Thrombosis. — Long B, Field SM, Singh M, Koyfman A. The American Journal of Emergency Medicine. 2024.
2. Cavernous Sinus Thrombosis. — Housley SB, McPheeters MJ, Raygor KP, et al. Neurosurgery Clinics of North America. 2024.
3. Septic Cavernous Sinus Thrombosis: Clinical Characteristics, Management, and Outcomes. — Halawa O, Gibbons A, Van Brummen A, Li E. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society. 2025.
4. Septic Cavernous Sinus Thrombosis: A Review. — Caranfa JT, Yoon MK. Survey of Ophthalmology. 2021.
5. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association. — Saposnik G, Bushnell C, Coutinho JM, et al. Stroke. 2024.
6. Septic Cerebral Venous Sinus Thrombosis. — Khatri IA, Wasay M. Journal of the Neurological Sciences. 2016.
7. Cerebral Venous Thrombosis. — Ropper AH, Klein JP. The New England Journal of Medicine. 2021.
8. Septic Cavernous Sinus Thrombosis Associated With Orbital Cellulitis: A Report of 6 Cases and Review of Literature. — Branson SV, McClintic E, Yeatts RP. Ophthalmic Plastic and Reconstructive Surgery. 2018.
9. The Clinical Characteristics, Implicated Pathogens and Therapeutic Outcomes of Culture-Proven Septic Cavernous Sinus Thrombosis. — Hsu CW, Tsai WC, Lien CY, Lee JJ, Chang WN. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2019.
10. Images of the Month: Cavernous Sinus Venous Thrombosis Secondary to Streptococcus Milleri Maxillary Sinusitis: An Unusual Cause of Diplopia and Headache. — Anton-Vazquez V, Dru R, Rich P, Arias M, Macallan D. Clinical Medicine. 2020.
11. Anticoagulation for Cavernous Sinus Thrombosis: A Systematic Review and Individual Patient Data Meta-Analysis. — Akarapas C, Wiwatkunupakarn N, Sithirungson S, Chaiyasate S. European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies : Affiliated With the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2025.
12. A Review of Eight Cases of Cavernous Sinus Thrombosis Secondary to Sphenoid Sinusitis, Including A12-Year-Old Girl at the Present Department. — Wang YH, Chen PY, Ting PJ, Huang FL. Infectious Diseases. 2017.
13. Septic Thrombosis of the Cavernous Sinuses. — Ebright JR, Pace MT, Niazi AF. Archives of Internal Medicine. 2001.
14. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. — Ferriero DM, Fullerton HJ, Bernard TJ, et al. Stroke. 2019.
15. ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions. — Pannell JS, Corey AS, Shih RY, et al. Journal of the American College of Radiology : JACR. 2024.
16. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. — Lansberg MG, O'Donnell MJ, Khatri P, et al. Chest. 2012.